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Objectives: Excessive daytime sleepiness (EDS) and sudden sleep onset (SOS) episodes are
frequent in Parkinson's disease (PD). The objectives are to identify clinical characteristics
and factors associated with EDS and SOS episodes.
Methods: Clinical demographic data were recorded (N¼100, mean age¼65.0710.4). EDS was
identiﬁed by the Epworth Sleepiness Scale (ESS410) and SOS episodes were registered. Disease
severity was evaluated by the Uniﬁed Parkinson's Disease Rating Scale (UPDRS, I, II, and III),
sleep disturbances by the Parkinson's Disease Sleep Scale (PDSSo100), depressive symptoms by
the Beck Depression Inventory (BDI410) and rapid eyemovement (REM) sleep behavior disorder
(RBD) by the REM sleep behavior scale. Levodopa equivalent dose was measured.
Results: PD patients with EDS (67%) were predominately male (73.1%) and had worse disease
severity (UPDRS II and III p¼ 0.005); SOS episodes (39%) were associated with disease duration,
diabetes, sleep disturbances (PDSS Scale), disease severity (UPDRS I, II, III) and RBD symptoms
(po0.05). Stepwise regression analysis showed that EDS was independently associated with
motor-symptoms severity (UPDRS III scale, p¼0.003). SOS episodes were independently asso-
ciated with disease duration (p¼0.006) and sleep disturbances (PDSS scale, p¼0.03): patients had
more uncomfortable immobility at night, tremor on waking and snoring or difﬁcult breathing.
Discussion: EDS and or SOS episodes are frequent and manifest a differential pattern in PD. SOS
episodes are associated with longer disease duration, diabetes, sleep disturbances and RBD
symptoms indicating that these “sleep attacks” are of multifactorial origin and probably
inﬂuenced by brain structural abnormalities.
& 2014 Brazilian Association of Sleep. Production and Hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Parkinson's disease (PD) presents with classical motor man-
ifestations that include tremor, rigidity, akinesia and postural
instability [1,2]. Several non-motor abnormalities, including
sleep alterations, such as, excessive daytime sleepiness (EDS),ep. Production and Hosti
licenses/by-nc-nd/3.0/).
edicina, Universidade Fe
V.M.S. de Bruin).“sleep attacks” or episodes of sudden onset of sleep (SOS),
insomnia, restless legs syndrome and rapid eye movement
sleep behavior disorder (RBD) have been described [3,4].
Importantly, EDS and SOS episodes greatly affect patients
and caregiver's routine and potentially increase the risk of
accidents [5]. To date, these alterations remain a challenge tong by Elsevier B.V. This is an open access article under the CC BY-
deral do Ceará, Rua Cel Nunes de Melo 1315, CEP 60.430-270
S l e e p S c i e n c e 7 ( 2 0 1 4 ) 1 3 – 1 814treatment as there is not enough evidence to make a
recommendation for the management of these sleep-wake
abnormalities [6]. Possibly, sleep and wake abnormalities
contribute to the heterogeneous clinical manifestations of
PD and to the common daytime oscillations of symptoms.
Thus, modifying factors that inﬂuence EDS and SOS episodes
may contribute to improve therapy.
Previous evidences indicate that EDS and SOS episodes
have a different pattern of manifestation in PD. For instance,
EDS is frequently found [7]; otherwise, SOS is less common
and manifests somewhat similar to narcoleptic events [8]. Of
note, the extent and severity of SOS in PD is variable: some
patients and caregivers inform long duration episodes with
atonia while others report episodes of short duration without
motor changes. Reports also suggest two distinct types of
events: those of sudden onset without warning and those of
slow onset with prodrome drowsiness [9]. Classical cataplec-
tic symptoms as occurs in narcolepsy have not been observed
in PD patients. Interestingly, a signiﬁcant higher narcolepsy
score in PD patients has been previously observed [10].
Clarifying whether clinical factors and associated comor-
bidities inﬂuence the manifestation of EDS and SOS episodes
in PD may contribute for patient care. The objectives of this
study are to characterize the clinical symptoms and to
identify factors contributing to the presence of EDS and SOS
in PD patients.2. Material and methods
2.1. Study design
This is an observational cross-sectional study of consecutive
patients with PD from an outpatient unit at a University
Hospital in the city of Fortaleza, Brazil. The study involved
100 patients recruited among a population of 152 patients:
28 were too old or had difﬁculty with verbal communication,
10 refused to collaborate and 14 were considered as poor-
compliant patients. Evaluations were performed over a period
of 12 months (July 2010 to July 2011). Subjects were selected
consecutively as part of a large cohort of patients with PD
being followed in a longitudinal study [Sleep-For-PD study].
Speciﬁc questionnaires were all measured concurrently in a
face-to-face interview by two trained medical staff. Patients
were excluded if they had any severe comorbidity and were
not competent to provide their informed consent. The proto-
col was analyzed and approved by the Ethics Committee
(HU-UFC No. 045.0607).
2.2. Measures
Demographic data, habits and comorbidities were recorded
using a standardized questionnaire. Daytime somnolence
was assessed by the Epworth Sleepiness Scale (ESS), a ques-
tionnaire containing eight items that ask about the expecta-
tion of dozing in eight hypothetical situations. An ESS score
Z10 indicates EDS [11]. Patients and family or caregivers were
interrogated about the presence of SOS or “sleep attacks”. We
used the Parkinson's Disease Sleep Scale (PDSS), a 15-item
visual analog scale that quantiﬁes several aspects ofnocturnal disabilities and sleep problems in PD; this scale
has also been validated in Brazil [12]. A PDSS score r100
deﬁned troublesome nocturnal symptoms and a cut-off ofo5
for each item indicated sleep impairment. Disease severity
was evaluated by the Uniﬁed Parkinson's Disease Rating
Scale (UPDRS) Parts I, II, III, IV and V. Depressive symptoms
were evaluated by the Beck Depression Inventory (BDI) and
were deﬁned as present if the score was BDI Z10 [12]. The
RBD scale that indicates clinically probable RBD was admi-
nistered to all patients. The Levodopa Equivalent Dose was
measured.
2.3. Statistical analysis
Descriptive statistics are presented as mean7standard devia-
tion, range and frequency (% values). Fisher's exact test for
categorical variables, Mann–Whitney U test for continuous
variables and Student's t-test for normally distributed data
with equal variances were performed to compare between
patients regarding the presence/absence of EDS and SOS
episodes. Logistic regression analysis examined each factor
associated with EDS or with SOS episodes. A forward step-
wise multiple regression analysis was later performed: vari-
ables with historical evidence of inﬂuence on sleepiness and/
or with a po0.10 were all included; a po0.05 was required for
a variable to be retained in the ﬁnal model. Statistical
analysis was carried out using SPSS for Windows, version
16.0. Statistical signiﬁcance was set at po0.05.3. Results
Patient characteristics according to the presence of EDS and
to SOS episodes are depicted in Table 1. Individuals with EDS
were predominately of male gender and had worse disease
severity as evaluated by UPDRS II and III. Patients with SOS
episodes had longer disease duration and worse severity of
symptoms as evaluated by the UPDRS I, II and III. They also
had more symptoms related to RBD (RBD scale). Logistic
regression analysis conﬁrmed an association between EDS
and symptom severity (UPDRS II and III). Sudden sleep onset
episodes were associated with disease duration, diabetes,
sleep disturbances (PDSS Scale), disease severity (UPDRS I, II
and III) and RBD symptoms (Table 2). Patients with SOS
episodes had more EDS (67%, Fisher's exact test, p¼0.02).
Stepwise analysis showed that EDS was independently asso-
ciated with motor symptoms severity (UPDRS III scale). SOS
episodes were independently associated with disease dura-
tion and sleep disturbances (PDSS scale) (Table 3). Analysis of
sleep disturbances showed that patients with SOS episodes
had more night symptoms related to uncomfortable immo-
bility, tremor on waking and snoring or difﬁcult breathing
(Fig. 1).4. Discussion
Our data conﬁrm that EDS and SOS episodes are frequent in
PD. SOS episodes affected nearly 40% of patients and this is in
agreement with a recent study involving a large number of PD
S l e e p S c i e n c e 7 ( 2 0 1 4 ) 1 3 – 1 8 15patients [8]. Several factors such as severity of motor and
non-motor symptoms, longer disease duration and the pre-
sence of diabetes were associated with SOS episodes. Also,
cases with SOS episodes had more sleep disturbances includ-
ing uncomfortable sensation and immobility at night, tremor
on waking, and snoring and sleep related breathing com-
plaints. All this conﬁrms the multifactorial origin of SOS
episodes in PD.
Presently, we show that PD patients with SOS have more
diabetes and longer disease duration. Previously, increased
daytime sleepiness has been shown in diabetes [13]. Com-
pared to individuals without diabetes, patients with diabetes
experience more EDS or dozing/sleeping episodes when
stopped for a few minutes in trafﬁc [14]. These ﬁndings
suggest that brain structural abnormalities play a role in
the multifactorial origin of SOS in PD. In partial agreement,
several studies show that low hypocretin levels in the CSF are
present in PD patients [15,16]. Normal levels and no associa-
tion with sleepiness have also been reported [17,18]. Low
hypocretin levels have been shown to correlate with
hypothalamic hypocretin cell loss in narcolepsy and other
forms of hypersomnia [19]. One cerebral histopathological
study has shown that a loss of hypocretin and melanin
concentrating hormone cells occurs in parallel with disease
progression in PD [20]. All these ﬁndings indicate that key
structures involved with the regulation of arousal and sleep
are compromised in PD, possibly, as part of the widespread
damage caused by neurodegeneration that occur not only in








Gender M/F 67/33 18/15 49/18
Age, mean (SD) 65.0 (10.4) 63.5 (8.4) 65.7 (11
Disease duration45 y,
Mean (SD)
6.8 (5.3) 19/12 31/36
LED Mean (SD) 707.1 (335.2) 709.7 (408.6) 705.0 (2
Family history (%) 28 9 19
Dyskinesia, (%) 36 10 26
UPDRS I, Mean (SD) 4.5 (2.8) 3.6 (2.2) 4.9 (2.9
UPDRS II, Mean (SD) 19.5 (9.9) 12.0 (6.3) 20.0 (9.
UPDRS III, Mean (SD) 17.3 (12.6) 12.4 (8.6) 22.5 (10
BDI, Mean (SD) 18.2 (12.0) 18.4 (10.4) 18.4 (10
PDSSo100 (N, %) 62 60 63
REMBD, Mean (SD) 6.2 (2.9) 5.7 (2.5) 6.6 (2.8
Visual hallucinations
N (%) 27 7 47/20
Vivid dreams, N (%) 57 19 38
Diabetes, N (%) 18 4 14
Hypertension, N (%) 45 12 33
Abbreviations: y¼years; LED¼Levodopa Equivalent Dose; UPDRS¼Uniﬁed
PDSS¼Parkinson's Disease Sleep Scale; REMBD¼Rapid eye Movement Sle
a Fisher's exact test.
b Student's t test.
c Mann–Whitney test.
n po0.05.
nn po0.01.Interestingly, it has been shown that the hypothalamic
hypocretinergic system promote motoneuron discharge and
have the capability of modulating the level of motor activity
through the ﬁnal common pathway i.e. inducing changes in the
synaptic responses and electrical properties of lumbar moto-
neurons. In short, the hypothalamic hypocretinergic neurons are
capable of modulating the activity of lumbar motoneurons
through presynaptic and postsynaptic mechanisms [22]. This is
of utmost importance considering that motor behavior altera-
tions are core symptoms in PD. According to Burgess et al. the
noradrenergic system acts to synchronize motor and arousal
systems. In this model, an excitatory noradrenergic drive main-
tains postural muscle tone during wakefulness by activating α1
receptors on skeletal motoneurons. Loss of this normal excita-
tory drive triggers motor inactivity during cataplexy by reducing
motoneuron excitation; hypocretin deﬁciency would cause cat-
aplexy by short-circuiting the noradrenergic drive to skeletal
motoneurons. It is suggested that the noradrenergic system
functions to couple the brain systems that control postural
muscle tone and behavioral arousal state [23]. Considering all
these ﬁndings, a narcolepsy-like pathophysiology of sleep-wake
disturbances and motor abnormalities could coexist in PD.
Furthermore, an independent association between SOS
episodes and sleep disturbances such as RBD symptoms
was observed. Cumulative evidence shows that RBD precedes
the development of PD by many years [24–26]. Previously, a
reduction of median cerebellar peduncle that carries key
structures from the reticular ascending activating system
has been associated with EDS in PD patients [27]. These factspiness and sudden sleep onset episodes in Parkinson's





0.04a,n 40/21 27/12 0.27a
.2) 0.34b 64.5 (10.3) 65.8 (10.5) 0.54
0.19a 37/23 13/25 0.01a,n
68.8) 0.96b 669.6 (195.3) 785.4 (524.0) 0.33b
0.94a 21 7 0.10a
0.65a 19 17 0.20a
) 0.06c 4.0 (2.7) 5.4 (2.7) 0.01c,n
0) 0.000c,nn 14.5 (9.2) 22.5 (9.1) 0.000c,nn
.6) 0.000c,nn 16.0 (12.6) 24.9 (10.5/ 0.000c,nn
.4) 0.84c 17.8 (11.3) 19.6 (10.2) 0.16c
0.80a 57 70 0.25a
) 0.15c 5.7 (2.6) 7.2 (2.8) 0.01c,n
0.62a 13 14 0.11a
0.82a 34 23 0.67a
0.40a 7 11 0.05a
0.37a 24 21 0.20a
Parkinson's Disease Rating Scale; BDI¼Beck Depression Inventory;
ep Behavior Disorder.
Table 2 – Logistic regression analysis of factors associated with excessive daytime sleepiness (Epworth Sleepiness
Scale410) and sudden sleep onset episodes.
Variables EDS SOS
OR [CI] P value OR [CI] P value
Gender 2.55 [1.05––6.20] 0.03n 1.74 [0.71–4.23] 0.22
Age 1.02 [0.97–1.06] 0.34 1.01 [0.97–1.05] 0.54
Disease duration 1.05 [0.96–1.14] 0.24 1.13 [1.03–1.23] 0.004nn
LED 1.00 [0.99–1.00] 0.96 1.00 [0.99–1.00] 0.33
Dyskinesia 1.33 [0.54–3.27] 0.53 1.74 [0.75–4.04] 0.19
Visual hallucinations 1.45 [0.54–3.93] 0.45 2.10 [0.85–5.19] 0.10
Vivid dreams 0.85 [0.35–2.05] 0.72 1.25 [0.54–2.90] 0.59
Diabetes 1.78 [0.53–5.99] 0.34 3.08 [1.06–8.91] 0.03n
Arterial hypertension 1.55 [0.64–3.79] 0.32 1.86 [0.79–4.35] 0.14
UPDRS I 1.20 [1.00–1.43] 0.04n 1.20 [1.02–1.40] 0.02n
UPDRS II 1.10 [1.04–1.17] 0.001nn 1.09 [1.03–1.14] 0.000nn
UPDRS III 1.08 [1.03–1.14] 0.001nn 1.06 [1.02–1.10] 0.002nn
BDI 0.99 [0.96–1.03] 0.96 1.01 [0.97–1.05] 0.44
PDSS 0.99 [0.97–1.00] 0.30 0.98 [0.96–0.99] 0.01n
REMBD 1.12 [0.96–1.32] 0.14 1.21 [1.03–1.42] 0.01n
Abbreviations: LED¼Levodopa Equivalent Dose; UPDRS¼Uniﬁed Parkinson's Disease Rating Scale; PDSS¼Parkinson's Disease Sleep Scale;
BDI¼Beck Depression Inventory; REMBD¼Rapid eye Movement Sleep Behavior Disorder.
n po0.05.
nn po0.01.
Table 3 – Multiple logistic regression analysis of factors inﬂuencing excessive daytime sleepiness and sudden sleep onset
episodes.
ESS410
N¼67 OR 95% CI P value
UPDRS III, range 1.08 1.02–1.14 0.003nn
Controlled for gender, age, disease duration, diabetes and REMBD symptoms
SOS episodes
N¼39 OR 95% CI P value
Disease duration, range (mean, SD) 1.13 1.03–1.24 0.006nn
PDSS, range (mean, SD) 0.98 0.96–0.99 0.03n
Controlled for gender, age, disease duration, diabetes and REMBD symptoms
Abbreviations: ESS¼Epworth Sleepiness Scale; SOS¼Sudden Sleep Onset; PDSS¼Parkinson's Disease Sleep Scale; REMBD¼Rapid eye Move-
ment Sleep Behavior Disorder.
n po0.05.
nn po0.01.
S l e e p S c i e n c e 7 ( 2 0 1 4 ) 1 3 – 1 816indicate that brain structure abnormalities are on the basis of
RBD and SOS in PD.
Controversy remains over the role of sleep apnea in EDS
and SOS episodes in PD. Previously, a study has shown that
snoring, an indicator of sleep apnea, was the only factor
associated with EDS in PD [28]. Recently, CPAP therapy
improved daytime sleepiness in patients with PD [29]. Impor-
tantly, it is essential to examine factors inﬂuencing not only
EDS but also the more severe SOS episodes. Potentially, SOS
episodes are more threatening and according to our data,
they are more related to disease duration and sleep distur-
bances. Another important issue is to investigate about the
presence of RBD that not only contribute for EDS and SOS
episodes but is closely related to the presence of sleep apnea.
All these issues are important to consider in future attemptsto modify EDS and SOS episodes in PD patients. For instance,
the effects of reducing overnight immobility and discomfort
on vigilance and daytime performance remain to be tested.
To date, no evidence has shown that increasing sleep quan-
tity and quality ameliorate EDS or SOS episodes in PD.
In this study, medication did not inﬂuence the severity of EDS
or the presence of SOS episodes. It is largely recognized that
dopamine agonists can precipitate these somewhat narcoleptic
events or “sleep attacks” in PD patients [30,31]. The effects of
dopamine agonists on sleep have been variable and possibly
related to the severity of baseline symptoms [32]. Improvement
of sleep symptoms and fatigue have been reported after the use
of dopamine agonists [33]. Ropinirole and other non-ergot
dopamine D2 receptor agonists cause selective loss of orexin-
immunoreactive neurons in culture of rat hypothalamus [34]. An
Fig. 1 – Patients with sudden sleep onset episodes have more uncomfortable immobility at night, tremor on waking, and
snoring and respiratory difﬁculties at night according to the evaluation of Parkinson's Disease Sleep Scale domains.
S l e e p S c i e n c e 7 ( 2 0 1 4 ) 1 3 – 1 8 17explanation for these ﬁndings may be a D2 receptor-mediated
presynaptic suppression of glutamatergic excitatory inputs to
orexin neurons causing silencing of excitatory activity of orexin
neurons and secondary depletion of orexin. This unwanted
dopamine agonist effect would further complicate the orexin
loss that occurs with PD neurodegeneration [35]. All this evidence
not only conﬁrms a disturbance of the orexinergic system and
secondary sleep/arousal cycle disruption but also shows a great
deal of clinical variability among patients. It is reasonable to
consider that EDS and/or SOS are not inﬂuenced only by the use
of dopaminergic agonists but by the disease process and the
several associated cerebral alterations that occur in PD [36,37].
Limitations to this study must be acknowledged. The
present data are based on the evaluation of a reduced
number of patients. However, the frequency of EDS and SOS
episodes are in agreement with a study involving a large
number of individuals [8]. Also, this study is based on
questionnaires and objective evidence obtained from poly-
somnography and multiple sleep latency tests would be of
interest. Of note, studies about the value of subjective
measures of sleepiness have led to the idea that objective
and subjective measures have different meaning [38,39].
Furthermore, an association between subjective sleep quality
and sleep measures obtained from polysomnography has not
been previously found [40]. It has been said that total
dopaminergic drug dose rather than the speciﬁc dopamine
agonist used is the best predictor of daytime sleepiness in PD
patients receiving dopamine agonist therapy [41].
In conclusion, we show that EDS and or SOS episodes in
PD are frequent and have a differential nature. SOS episodes
are associated with longer disease duration, diabetes, sleep
disturbances and RBD symptoms. Brain structural abnormal-
ities and hypocretin deﬁciency probably inﬂuence other
environmental factors. This survey strongly suggests that
SOS is a multifactorial phenomenon. The therapeutic man-
agement of EDS and SOS episodes in PD should consider that
these symptoms can be severe and unexpected and all
aggravating factors must be considered.Acknowledgments
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